title: Effects of albumin 5% and artificial colloids on clot formation in small infants.
abstract: Albumin is often cited in textbooks as the gold standard for fluid replacement in paediatrics, but in practice artificial colloids are more frequently used. Although one concern with the use of artificial colloids is their intrinsic action on haemostasis, the available data in children are inconclusive for 6% hydroxyethyl starch 130/0.4 (HES) and no data exist for gelatine solution with respect to coagulation. A total of 42 children (3-15 kg) undergoing surgery and needing colloid replacement were randomly assigned to receive 15 mlxkg(-1) of either albumin 5%, 4% modified gelatine solution or 6% hydroxyethyl starch 130/0.4 solution. Standard coagulation tests and modified thrombelastography (ROTEM) were performed. After colloid administration, routine coagulation test results changed significantly and comparably in all groups, although activated partial thromboplastin time values increased more with gelatine and HES. Coagulation time was unchanged in the children who received albumin or gelatine but other activated modified thrombelastography values were significantly impaired in all groups. After gelatine and after albumin the median clot firmness decreased significantly but remained within the normal range. Following HES, coagulation time increased significantly, and clot formation time, alpha angle, clot firmness, and fibrinogen/fibrin polymerisation were significantly more impaired than for albumin or gelatine, reaching median values below the normal range. From a haemostatic point of view it might be preferable to use gelatine solution as an alternative to albumin; HES showed the greatest effects on the overall coagulation process.
authors.affiliation: Department of Anaesthesiology and Intensive Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. thorsten.haas@i-med.ac.at
authors.forename: T
authors.initials: T
authors.lastname: Haas
authors.forename: A
authors.initials: A
authors.lastname: Preinreich
authors.forename: E
authors.initials: E
authors.lastname: Oswald
authors.forename: W
authors.initials: W
authors.lastname: Pajk
authors.forename: J
authors.initials: J
authors.lastname: Berger
authors.forename: G
authors.initials: G
authors.lastname: Kuehbacher
authors.forename: P
authors.initials: P
authors.lastname: Innerhofer
mesh_terms: D000418:Albumins / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D003102:Colloids / Q000494:pharmacology*; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D005780:Gelatin / Q000494:pharmacology; D006488:Hemostasis, Surgical; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology; D007223:Infant; D007430:Intraoperative Care / Q000379:methods; D008297:Male; D010952:Plasma Substitutes / Q000494:pharmacology*; D013386:Succinates / Q000494:pharmacology; D013916:Thrombelastography
chemical_list: D000418:Albumins; D003102:Colloids; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D013386:Succinates; C060085:succinylated gelatin; D005780:Gelatin